Loading…
Loading…
MSSV (Meso Numismatics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MSSV does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MSSV and 80,000+ other tickers.
See exactly how MSSV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MSSV and 80,000+ other tickers.
Meso Numismatics, Inc. operates with a distinctive dual focus. Primarily, it engages in the numismatic sector, serving both domestic and international markets. Its offerings include a variety of collectible items such as coins, paper currency, precious metals (bullion), and medals, which are primarily sold via live auctions. Complementing its auction activities, the company provides a specialized banknote scanner application designed to identify crucial characteristics of currency. Furthermore, it maintains an e-commerce presence through its website, mesocoins.com, for direct product sales…
We are thrilled to announce our corporate name change from Meso Numismatics, Inc. to Regenerative Medical Technology Group LAS VEGAS, NV / ACCESSWIRE / October 21, 2024 / Regenerative Medical Technology Group Inc. ("Regen Med Tech Group" or the "Company"), formerly "Meso Numismatics, Inc. ($MSSV), a renowned leader in regenerative medicine, is pleased to announce that it has changed its name to Regenerative Medical Technology Group ($RMTG). This corporate action will take effect at the open of business on 10/21/2024.
Regenerative Medical Technology Group, is pleased to announce Global Stem Cells Group's (GSCG) launch of Cellgenic's three prominent Regenerative Medicine Events in Peru this September. LAS VEGAS, NV / ACCESSWIRE / September 9, 2024 / Meso Numismatics, Inc. ("Meso Numismatics" or the "Company") (MSSV), a renowned leader in regenerative medicine, and in the process with FINRA of a name change to Regenerative Medical Technology Group, is pleased to announce Global Stem Cells Group's (GSCG) launch of Cellgenic's three prominent Regenerative Medicine Events in Peru this September.
LAS VEGAS, NV, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a renowned leader in regenerative medical company, and in the process with FINRA of a name change to Regenerative Medical Technology Group, is pleased to announce Global Stem Cells Group's (GSCG) launch of its innovative Cellgenic peptide line. Cellgenic, the division of GSCG that promotes and distributes innovative products and equipment for physicians in the field of regenerative medicine, introduces this new line of peptides, once again solidifying its mission to provide physicians with cutting-edge solutions to improve patient care.
LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company's business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov .
LAS VEGAS, NV , Jan. 31, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company, is pleased to announce that it closed its 2023 fiscal year with approximately $2.4 million in sales, a more than 50% increase over 2022 levels. Sales were derived from its 4 main channels, Training, Product sales, Equipment sales and Patient procedures. The Company expects to reach $5 million in revenues with approximately $1 million in operating profits (defined as gross profit less total operating expenses) for its fiscal year 2024. Although overall sales are expected to increase, the significant sales increase is expected to come from the patient procedure category as the Company's Cancun based clinic starts to increase the total number of monthly patient procedures.